Key result
The ABVG regimen (gemcitabine added to doxorubicin, bleomycin, and vinblastine) caused significant pulmonary toxicity in 5 of 12 patients, indicating it should not be pursued for de novo HD.
Why the study?
Is the ABVG regimen (substituting gemcitabine for dacarbazine) safe and tolerable for patients with newly diagnosed, high-risk Hodgkin disease?
Is the ABVG regimen (substituting gemcitabine for dacarbazine) safe and tolerable for patients with newly diagnosed, high-risk Hodgkin disease?
Answers are grounded in this paper and cite their sources.
The combination of bleomycin and gemcitabine causes significant pulmonary toxicity and should not be pursued for de novo Hodgkin disease.
BACKGROUND: Gemcitabine is an effective treatment for recurrent Hodgkin disease (HD), with relatively minimal associated toxicity. The authors conducted a trial substituting this drug for dacarbazine in the standard regimen to form ABVG (doxorubicin, bleomycin, vinblastine, gemcitabine) for patients with newly diagnosed, high-risk HD. METHODS: Twelve patients (median age, 34 years) with advanced-stage de novo HD were enrolled. Standard doses of doxorubicin, bleomycin, and vinblastine were given for six cycles. Cohorts of three patients were enrolled and the dose of gemcitabine was escalated to identify the maximally tolerated dose in this combination. RESULTS: The maximally tolerated dose of gemcitabine was determined to be 800 mg/m(2) in this combination. Five patients developed clinically significant pulmonary toxicity. Three required hospitalization during the final two cycles of treatment. Pneumonitis could not be predicted with serial diffusion capacity for carbon monoxide (DECO) evaluations, and reversed after discontinuation of bleomycin in three patients and steroid therapy in two patients. All 12 patients are alive to date, and 4 patients have experienced disease progression. CONCLUSIONS: The bleomycin/gemcitabine combination should not be pursued for de novo HD due to significant pulmonary toxicity.
No takes yet. Share an insight, caveat, or question.
Friedberg et al. (2003) studied de novo Hodgkin disease (n=12). ABVG (doxorubicin, bleomycin, vinblastine, gemcitabine) was evaluated on maximally tolerated dose and toxicity. The ABVG regimen (gemcitabine added to doxorubicin, bleomycin, and vinblastine) caused significant pulmonary toxicity in 5 of 12 patients, indicating it should not be pursued for de novo HD.
Synapse has enriched 10 related papers. Consider them for comparative context: